Home Featured 2

Featured 2

Featured posts

Random

Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories

lungcanc

Sublobar Resections for Early Lung Cancer

Q&A with Lead ALCHEMIST Investigator, Dr. Ramaswamy Govindan

PD-L1 in Cytology Specimens

Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

A Roadmap to Improving Lung Cancer Care in the Middle East...

lungcanc

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS...

lungcanc

Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A...

lungcanc

Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin...

lungcanc

The IASLC and the International Thoracic Oncology Nursing Forum: Celebrating Collaboration

lungcanc

An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old...

lungcanc

Stage IIIA NSCLC: A Review of Recent and Ongoing Trials Trial

lungcanc

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

lungcanc

U.S. Drug Approvals: 2010 – 2020

lungcanc

Understanding the Effects of Time to Surgery on Upstaging for Stage...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib